Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience
Sunshine Biopharma (NASDAQ:SBFM) announced on October 14, 2025 that its Board approved a $5 million strategic investment in Bitcoin (BTC) as a treasury reserve asset.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sunshine Biopharma (NASDAQ:SBFM) announced on October 14, 2025 that its Board approved a $5 million strategic investment in Bitcoin (BTC) as a treasury reserve asset.
The Company said the $5 million position will be acquired over time via a regulated digital asset custodian or by buying an ETF or proxy stock, and that it may allocate additional funds to increase Bitcoin holdings in the future. Management framed the move as a hedge and a high-conviction asset to strengthen the company's financial foundation while continuing focus on its drug development pipeline, including antiviral small molecules and mRNA-based cancer therapies.
Positive
- Board-approved $5 million allocation to Bitcoin
- Plan to increase holdings over time as funds become available
- Execution flexibility via custodian, ETF, or proxy stock
Negative
- None.
Details
News Market Reaction – SBFM
On Oct 14, the day this news came out, SBFM closed 15.38% above the previous close.
Data tracked by StockTitan Argus for the Oct 14 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced its Board of Directors has formally approved a strategic investment of
The Company's Bitcoin investment of
"We view Bitcoin not just as a hedge, but as a high-conviction asset with asymmetric upside," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "In an environment of persistent monetary expansion, Bitcoin offers a unique combination of scarcity, liquidity, and global accessibility. It's a natural complement to our long-term capital strategy."
The Company remains fully committed to its core mission of delivering life-saving therapeutics and will continue to focus on its drug development pipeline, including its antiviral small molecules, mRNA-based cancer therapies, and generic drug portfolio.
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 74 generic prescription drugs on the market in Canada and more than 12 additional drugs planned to be launched in 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.